Oleclumab
Phase 3Monoclonal antibody
AstraZenecaOleclumab is an experimental drug being tested to treat certain types of cancer by helping the immune system recognize and attack cancer cells.[1] Oleclumab is currently being investigated across 8 indications[3], with its most advanced program in Phase 3.[1]
Oleclumab is one of 228 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.
8
Indications
23
Total Trials
14
Active Trials
227
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Oleclumab
AstraZenecaPhase 3
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Acupan
YYonsei University
Preclinical
Avastin
RochePreclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Breast Cancer2 trials
Chemotherapy2 trials
Advanced Solid Tumors2 trials
9 more indications
Advanced Solid Malignancies1 trial
Bladder Cancer1 trial
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Completed·—·Phase 1·NCT03773666·12 enrolled
Durvalumab1 trial
Phase II1 trial
Pancreatic Cancer1 trial
Carcinoma, Non-Small-Cell Lung1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oleclumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 5'-Nucleotidase Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company